N@N

PlanClear Releases In-Depth Study on Positron; 2010 Progress and Strong Market Position Cited

^{Published on 2010-12-02 16:45:38 - Market Wire}
 

INDIANAPOLIS--([ BUSINESS WIRE ])--Positron Corporation (OTCBB:POSC), a leading molecular imaging company specializing in the field of nuclear cardiology, today announced the release of a report by PlanClear which studied Positrona™s 2010 accomplishments and unique market position.

"Wea™re thrilled to receive such validation a" as the studya™s findings only served to further reinforce our confidence in the path we have only just begun to forge."

The comprehensive 50-plus page report was prepared by PlanClear, a strategic growth management firm that specializes in nuclear medicine industry. PlanClear provides strategic consulting, marketing and research services aimed specifically at affording companies the critical insight necessary to formulate business strategies that will promote sustainable, strong growth.

The PlanClear report highlighted Positrona™s achievement of three critical benchmarks:

1. the sale of 15 PET Camera systems within one year after receiving FDA approval;

2. the elimination of debt and strengthening the POSC balance sheet; and,

3. successful R&D efforts resulting in a new product launch that will automate the SPECT dispensing process.

aWe wanted an independent study done by a company well versed on, and well respected in, the nuclear medicine field and the rapidly changing dynamics at play in the sector,a said Positron CEO Patrick G. Rooney. aWea™re thrilled to receive such validation a" as the studya™s findings only served to further reinforce our confidence in the path we have only just begun to forge.a

PlanCleara™s analysis demonstrated the continued market movement towards PET from SPECT resulting in nearly 50% of the entire cardiac SPECT market transitioning to PET within the next decade. While PlanClear believes SPECT will gradually decline in the next decade, it should continue to play an important role in nuclear medicine. More specifically, the report cites the SPECT value chain will be altered via automation, with radiopharmaceutical intermediaries eliminated and direct customer access established between generator manufacturers and end users. Positrona™s newly launched product should play a critical role in the SPECT value chain transformation.

aWithin a yeara™s time Positron has positioned itself as a formidable player in the high-potential, emerging PET camera market. The Company exhibited significant growth during 2010, all while carefully laying the foundation and paving the inroads for continued future successes. A year marked by considerable change in the nuclear medicine industry and a punishing recession, makes the Companya™s achievements all the more impressive,a said PlanClear CEO Al Naqvi.

The Company noted the full-version report contained certain information of a proprietary nature and noted a summary version of the report can be found at [ http://pclear.files.wordpress.com/2010/11/positron-growthreport1.pdf ].

About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron products include: the Attrius®, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assista", a radiopharmaceutical injection shield. More information about Positron is available at [ www.positron.com ].

About PlanClear:a growth management firm that specializes in nuclear medicine industry, PlanClear enables companies to more quickly achieve sustainable and strong growth.The company offers the following services: strategic growth consulting, growth capital advisory, merger and acquisition strategy, new product success management, growth risk management and analysis, international growth management, and growth impact on stock value studies.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.

For further information please contact Positron Corporation at (317)576-0183.